Cysteine Hydrochloride
FDA-approved product (injectable, injection), marketed as Cysteine Hydrochloride, Elcys, Nouress.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 0 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Liver disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- Anti-infective classification
- Neither a WHO ATC code nor an FDA pharmacologic class was found for it, so whether it is already an antimicrobial is not established. It needs review and is not counted as a repurposing candidate.
Repurposing investigation
No supported pathogen reaches ≥40% AI-predicted activity for Cysteine Hydrochloride, so it is not among the repurposing candidates. Its predictions are shown below.
AI-predicted activity
AI prediction · nothing measured- MRSA9.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli8.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae8.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis17.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Cysteine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Assessment of the Safety and Efficacy of DERMASTREAM™ - ENZYSTREAM™ System for the Treatment of Chronic Venous Ulcers
NCT00485329 · start 2007-07
Registered record
- Registry ID
- NCT00485329
- Conditions
- Lower Extremity Chronic Venous Ulcers
- Interventions
- Papain; Papain; Papain
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Completed
- Start
- 2007-07
- Completion
- 2009-03
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionLower Extremity Chronic Venous UlcersInterventionPapain; Papain; PapainPhasePhase 1 / Phase 2Registry statusCompletedN-acetyl-cysteine (NAC) and Kidney Graft Function
NCT00998972 · start 2006-09
Registered record
- Registry ID
- NCT00998972
- Conditions
- Brain Death; Chronic Renal Insufficiency
- Interventions
- N-acetylcysteine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2006-09
- Completion
- 2011-06
- Enrolment
- 236
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBrain Death; Chronic Renal InsufficiencyInterventionN-acetylcysteinePhasePhase 3Registry statusCompletedN-acetylcysteine in Liver Transplantation
NCT00736541 · start 2004-07
Registered record
- Registry ID
- NCT00736541
- Conditions
- End Stage Liver Failure
- Interventions
- N-acetylcysteine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2004-07
- Completion
- 2008-01
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionEnd Stage Liver FailureInterventionN-acetylcysteinePhaseNot applicableRegistry statusCompletedN-Acetylcysteine for Preventing Renal Injury After Cardiac Surgery
NCT00188630 · start 2003-07
Registered record
- Registry ID
- NCT00188630
- Conditions
- Heart Disease; Acute Renal Failure
- Interventions
- N-acetylcysteine; 5% dextrose solution
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2003-07
- Completion
- 2007-07
- Enrolment
- 176
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHeart Disease; Acute Renal FailureInterventionN-acetylcysteine; 5% dextrose solutionPhasePhase 3Registry statusCompletedCombination Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00003346 · start 1997-11
Registered record
- Registry ID
- NCT00003346
- Conditions
- Melanoma (Skin)
- Interventions
- acetaminophen; acetylcysteine; carmustine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1997-11
- Completion
- 2003-02
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMelanoma (Skin)Interventionacetaminophen; acetylcysteine; carmustinePhasePhase 2Registry statusCompleted